Pharmacometrics at FDA: Evolution and Impact on Decisions

Drug development and regulatory decisions are driven by information that is compiled primarily from clinical trials and other supportive experiments, but also through clinical experience in the post‐market period. The wisdom of these decisions determines the efficiency of drug development, the decision to approve the drug, and the resultant drug product quality including guidance on how to use the product known as the label. Although the decisions are usually simple in nature (e.g., trial design and project progression at the company, product and labeling approval at the Food and Drug Administration (FDA)), the information informing the decision is complex and diverse.

[1]  C. T. Viswanathan,et al.  Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.

[2]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[3]  Yaning Wang,et al.  Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications , 2005, The AAPS Journal.

[4]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[5]  Innovation OR Stagnation.  Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[6]  John J. Smith,et al.  Defining "least burdensome means" under the Food and Drug Administration Modernization Act of 1997. , 2000, Food and drug law journal.

[7]  Robert M Califf,et al.  Peer-reviewed publication of clinical trials completed for pediatric exclusivity. , 2006, JAMA.

[8]  D. Rubin,et al.  Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval , 2003, Clinical pharmacology and therapeutics.

[9]  C Garnett,et al.  Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.

[10]  P. Marroum,et al.  Utilisation of Pharmacokinetic-Pharmacodynamic Modelling and Simulation in Regulatory Decision-Making , 2001, Clinical pharmacokinetics.